BRCA2 and cancer: There were 172 women (mean [SD] age, 47.1 [11.7] years) treated with BCT who had pathogenic BRCA variants identified using the Clinical Cancer Genetics Program Database; 92 (53.5%) had BRCA1 variants and 80 (46.5%) had BRCA2 variants (Table 1).